New Prognostic Model Outperforms Established Predictive Models in MDS
In a study published in the Journal of Clinical Oncology, researchers reported that a newly developed personalized prediction model comprising clinical and genomic data...
Therapeutic Anticoagulation Does Not Prevent PVT Recurrence After Liver Transplant
In patients with cirrhosis who have portal vein thrombosis (PVT) and undergo liver transplantation, therapeutic anticoagulation was associated with significantly higher rates of bleeding...
Study Explores Molecular Landscape, Prognostic Impact of FLT3-ITD Insertion Site in Patients With AML
In an analysis of the phase III RATIFY trial published in Leukemia, researchers examined the molecular landscape of FLT3 internal tandem duplication (ITD) mutations...
Is Dose-Dense BV-ICE an Effective Salvage Option in Relapsed/Refractory Classical Hodgkin Lymphoma?
For patients with relapsed/refractory classical Hodgkin lymphoma (cHL), second-line therapy with a combination of intensive dose-dense brentuximab vedotin (BV) and ifosfamide, carboplatin, and etoposide...
Evaluating Venetoclax Plus Daratumumab and Dexamethasone in Relapsed/Refractory MM
Treatment with oral BCL-2 inhibitor venetoclax induced deep and durable responses in patients with relapsed or refractory multiple myeloma (MM), especially those with t(11;14)...
Patient-Reported Outcome Questionnaire Shows Promise for Monitoring ITP
A draft version of a 10-item patient-reported outcome (PRO) questionnaire has been developed to evaluate the impact of immune thrombocytopenia (ITP) on patients and...
Cognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma
Patients with lymphoma tend to report and show signs of worsening cognitive function at six months after chemotherapy compared with healthy controls, according to...
Circulating Tumor DNA After Axi-Cel Stratifies Risk, Predicts Outcomes in LBCL
While many patients with relapsed/refractory large B-cell lymphoma (LBCL) respond to treatment with axicabtagene ciloleucel (axi-cel), only a small subset of these responders experience...
Daratumumab Plus CyBorD Improves Outcomes in Newly Diagnosed Light-Chain Amyloidosis
Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone (CyBorD) resulted in higher rates of hematologic response as well as improved survival free from hematologic progression...
Second-Line Pembrolizumab Plus GVD in Relapsed/Refractory Classical Hodgkin Lymphoma
Second-line pembrolizuab plus intravenous (IV) gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) led to high complete response (CR) rates in patients with relapsed/refractory classical Hodgkin...
Current Issue
October 2021, Volume 7, Issue 12
This issue tells the long story of drug shortages, demystifies transfusion services, and more.